The History of MDMA as an Underground Drug in the United States, 1960–1979

References

• Alles, G. A. 1959. Some relations between chemical structure and physiological action of mescaline and related compounds. In Neuropharmacology, ed. H. A. Abramson, 181–204. New York: Josiah Macy Foundation.
   Google Scholar
• Anderson, G. M., G. Braun, U. Braun, D. E. Nichols, and A. T. Shulgin. 1978. Absolute configuration and psychotomimetic activity. In QuaSAR: Quantitative structure-activity relationships, eds. G. Barnett, M. Trsic, and R. Willette, 8–15. Washington, DC: NIDA.
   Google Scholar
• Anonymous. 1973. Basic drug manufacture. Manhattan Beach, CA: 20th Century Alchemist.
   Google Scholar
• Anonymous. 1981. Ecstasy: Everything looks wonderful when you’re young and on drugs. WET Magazine, September/October 1981 issue: 76.
   Google Scholar
• Bailey, K., A. W. By, D. Legault, and D. Verner. 1975. Identification of the N-methylated analogues of the hallucinogenic amphetamines and some isomers. JAOAC 58:62–69.
   PubMedGoogle Scholar
• Beck, C. 1997/1998. MDMA: Die frühen Jahre. Yearbook for Ethnomedicine and the Study of Consciousness 6 (7):95–125.
   Google Scholar
• Beck, J., and M. Rosenbaum. 1990. The scheduling of MDMA (“ecstasy”). In The handbook of drug control in the United States, ed. J. Inciardi, 306–15. Westport, CT: Greenwood Press.
   Google Scholar
• Beck, J., and M. Rosenbaum. 1994. Pursuit of ecstasy. Albany, NY: State University of New York Press.
   Google Scholar
• Benzenhöfer, U., and T. Passie. 2006. Zur Frühgeschichte von “ecstasy.” Nervenarzt 77:95–95 and 98–99. doi:10.1007/s00115-005-2001-y.
   PubMed Web of Science ®Google Scholar
• Benzenhöfer, U., and T. Passie. 2010. Rediscovering MDMA (ecstasy): The role of the American chemist Alexander T. Shulgin. Addiction 105:1355–61. doi:10.1111/add.2010.105.issue-8.
   PubMed Web of Science ®Google Scholar
• Bernschneider-Reif, S., F. Oxler, and R. W. Freudenmann. 2006. The origin of MDMA (“ecstasy”): Separating the facts from the myth. Pharmazie 61:966–72.
   PubMed Web of Science ®Google Scholar
• Biniecki, S., and E. Krajewski. 1960. Preparation of dl-1-(3,4-methylenedioxyphenyl)-2-(methylamino)-propane and dl-(3,4-dimethoxyphenyl)-2-(methylamino)-propane. Acta Poloniae Pharmaceutica 17:421–25.
   Google Scholar
• Clegg, M. 2013. Interview with Torsten Passie. Atlanta, GA, December 20, 2013.
   Google Scholar
• Cook, L., and E. J. Fellows 1961. Anorexigenic preparation and a method of curbing the appetite. U.S. Patent 2-974-148.
   Google Scholar
• Department of Health and Human Services. 1984. Phenethylamines. Rockville, MD: Department of Health and Human Services.
   Google Scholar
• Drug Control Section DEA. 1984. Schedule I control recommendation under the CSA for 3,4,-methylenedioxymethamphetamine (MDMA). Washington, DC: Department of Justice, Drug Enforcement Agency (DEA).
   Google Scholar
• Dye, C. 1982. MDA/MDM: The chemical pursuit of ecstasy. Drug Survival News 10 (5):8–9.
   Google Scholar
• Eichmeier, L. S., and M. E. Caplis. 1975. Forensic chemist: Analytical detective. Analytical Chemistry 47:841A–844A. doi:10.1021/ac60359a050.
   Web of Science ®Google Scholar
• Eisner, B. 1989. Ecstasy: The MDMA story. Berkeley, CA: Ronin.
   Google Scholar
• Forte, R. 2013. Interview with Torsten Passie. Santa Monica, CA, December 18, 2013.
   Google Scholar
• Frank, R. S. 1983. The clandestine drug laboratory situation in the United States. Journal of Forensic Sciences 28:18–31. doi:10.1520/JFS12235J.
   PubMed Web of Science ®Google Scholar
• Friedhoff, A. J., F. A. Lynn, G. Rosenblatt, and A. Holden. 1958. Preliminary study of a new anti-depressant drug. The Journal of Nervous and Mental Disease 127:185–90. doi:10.1097/00005053-195808000-00011.
   PubMed Web of Science ®Google Scholar
• Gaston, T. R., and G. T. Rasmussen. 1972. Identification of 3,4-methylenedioxymethamphetamine. Microgram 5:60–63.
   Google Scholar
• Hardman, H. F., C. O. Haavik, and M. H. Seevers. 1973. Relationship of the structure of mescaline and seven analogs to toxicity and behavior in five species of laboratory animals. Toxicology and Applied Pharmacology 25:299–309. doi:10.1016/S0041-008X(73)80016-X.
   PubMed Web of Science ®Google Scholar
• Kau, G. 2008. Flashback to the Federal Analog Act of 1986: Mixing rules and standards in the Cauldron. University of Pennsylvania Law Review 156:1077–115.
   Web of Science ®Google Scholar
• Kirsch, M. M. 1986. Designer drugs. Minneapolis, MN: CompCare Publications.
   Google Scholar
• Klein, J. 1985. The new drug they call “ecstasy.” New York Magazine, May 20, 1985.
   Google Scholar
• Langs, J. 1961. Preparation of DL-I-(3,4-methylenedioxyphenyl)-2-(methylamino)propane and DL-I-(3,4-dimethoxyphenyl)-2-(methylamino)propane. Chemical Abstracts 14350:e.
   Google Scholar
• Leary, L. 1985. XTC: The drug of the 80s. DOP E Magazine, July 1985 issue: 75-76.
   Google Scholar
• Metzner, R. 1983. Psychedelics and spirituality. Lecture at the Psychedelics and Spirituality Conference, Santa Barbara, CA, May 1983.
   Google Scholar
• Meyers, F. H., A. J. Rose, and D. E. Smith. 1967. Incidents involving the Haight-Ashbury population and some uncommonly used drugs. Journal of Psychedelic Drugs 1:136–46.
   Google Scholar
• Naranjo, C., A. T. Shulgin, and T. Sargent. 1967. Evaluation of 3,4-methylenedioxyamphetamine (MDA) as an adjunct to psychotherapy. Medical Pharmacology Experiments 17:359–64.
   PubMedGoogle Scholar
• Nichols, D. 2013. Interview with Torsten Passie, December 12, 2013.
   Google Scholar
• Nichols, D. E. 1986. Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens: Identification of a new therapeutic class: Entactogens. Journal of Psychoactive Drugs 18:305–13. doi:10.1080/02791072.1986.10472362.
   PubMed Web of Science ®Google Scholar
• Pentney, A. R. 2001. An exploration of the history and controversies surrounding MDMA and MDA. Journal of Psychoactive Drugs 33:213–21. doi:10.1080/02791072.2001.10400568.
   PubMed Web of Science ®Google Scholar
• Pharm Chem Laboratories. 1985. MDMA analyzed. Pharm Chem Newsletter 14 (3):5.
   Google Scholar
• Pilcher, T. 2008. e: The incredible strange history of ecstasy. London: Running Press.
   Google Scholar
• Renfroe, C. L. 1986. MDMA on the street: Analysis Anonymous®. Journal of Psychoactive Drugs 18:363–69. doi:10.1080/02791072.1986.10472371.
   PubMed Web of Science ®Google Scholar
• Richards, R. N. 1971. MDA and its relationship to other psychedelics. Addictions 18:11–15.
   Google Scholar
• Salt and Pepper Syndicate. 1976. Hallucinogenic and psychedelic drug synthesis manual. O.O.: Salt and Pepper Syndicate.
   Google Scholar
• Saunders, N., and P. Walder. 1994. Ecstasy. Zürich: Ricco Bilger.
   Google Scholar
• Seymour, R. 1986. MDMA. San Francisco: self-published.
   Google Scholar
• Shulgin, A. T. 1960–1976. Laboratory notebook 1. https://www.erowid.org/library/books_online/shulgin_labbooks/shulgin_labbook1_orig.pdf, accessed 05-05-2015.
   Google Scholar
• Shulgin, A. T. 1978. Psychotomimetic drugs: Structure–activity relationships. In Handbook of Psychopharmacology, vol. 11: Stimulants, eds. L. Iversen, S. D. Iversen, and S. H. Snyder, 243–333. New York: Plenum.
   Google Scholar
• Shulgin, A. T. 1986. The background and chemistry of MDMA. Journal of Psychoactive Drugs 18:291–304. doi:10.1080/02791072.1986.10472361.
   PubMed Web of Science ®Google Scholar
• Shulgin, A. T. 1990. History of MDMA. In Ecstasy: The clinical, pharmacological and neurotoxicological effects of the drug MDMA, ed. S. J. Peroutka, 1–20. Boston: Kluwer Academic Publishers.
   Google Scholar
• Shulgin, A. T. 1997. Die frühe geschichte von MDMA. In Ecstasy: Design für die Seele?, eds. J. Neumeyer, and H. Schmidt-Semisch, 97–105. Freiburg im Breisgau, Germany: Lambertus.
   Google Scholar
• Shulgin, A. T., U. Braun, and G. Braun. 1978. N-substituted analogs of 3,4-methylenedioxyphenylisopropylamine. Presented at the American Chemical Society Conference, Anaheim, CA, March 1978.
   Google Scholar
• Shulgin, A. T., and D. E. Nichols. 1978. Characterization of three new psychotomimetics. In The psychopharmacology of hallucinogens, eds. R. C. Stillman and R. E. Willette, 74–83. New York: Pergamon Press.
   Google Scholar
• Shulgin, A. T., and A. Shulgin. 1991. PHIKAL. Berkeley, CA: Transform Press.
   Google Scholar
• Shulgin, L. A. 2013. Interview mit Torsten Passie, Alexander Shulgin Research Institute (ASRI). Lafayette, California, December 10, 2013.
   Google Scholar
• Siegel, R. K. 1986. MDMA: Nonmedical use and intoxication. Journal of Psychoactive Drugs 18:349–54. doi:10.1080/02791072.1986.10472368.
   PubMed Web of Science ®Google Scholar
• Silcott, P., and M. Silcott. 2000. The book of E: All about ecstasy. London: Omnibus Press.
   Google Scholar
• Smith, Kline & French Laboratories. 1957. Report on clinical evaluation of SKF #5 (Amphedoxamine). Philadelphia, PA: Smith, Kline & French Laboratories.
   Google Scholar
• Smith, M. V. 1973. Psychedelic chemistry. San Francisco, CA: Rip Off Press.
   Google Scholar
• Sreenivasan, V. R. 1972. Problems in identification of methylenedioxy and methoxy amphetamines. The Journal of Criminal Law 63:304–12.
   Google Scholar
• Stafford, P. 1992. Psychedelics encyclopedia. Berkeley, CA: Ronin.
   Google Scholar
• Stolaroff, M. 2004. The secret chief revealed. Sarasota, FL: MAPS.
   Google Scholar
• Student Association for the Study of Hallucinogens. 1974. MDA: A different psychedelic‬. Madison, WI: STASH Press.
   Google Scholar
• Turek, I. S., R. A. Soskin, and A. A. Kurland. 1974. Methylenedioxyamphetamine (MDA)–Subjective effects. Journal of Psychoactive Drugs 6:7–14. doi:10.1080/02791072.1974.10471499.
   Web of Science ®Google Scholar
• Weil, A. T. 1976. The love drug. Journal of Psychoactive Drugs 8:335–37. doi:10.1080/02791072.1976.10471861.
   Web of Science ®Google Scholar
• Wilkinson, P. 2001. The acid king. Rolling Stone, July 5, Issue 872, 113–23.
   Google Scholar
• Yensen, R., F. B. Di Leo, J. C. Rhead, W. A. Richards, R. A. Soskin, B. Turek, and A. A. Kurland. 1976. MDA-assisted psychotherapy with neurotic outpatients: A pilot study. The Journal of Nervous and Mental Disease 163:233–34. doi:10.1097/00005053-197610000-00002.
   PubMed Web of Science ®Google Scholar